TolerogenixX GmbH has developed a patented and clinically
TolerogenixX has raised $7.6M in total funding. The most recent round was Series A. The last funding was announced in July 2023.
TolerogenixX's investors include HTGF (High-Tech Gruenderfonds), Kalodion GmbH, CVentures, Biotech Mountains, NISUS.
TolerogenixX is headquartered in Heidelberg, Germany.
TolerogenixX GmbH has developed a patented and clinically
TolerogenixX is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TolerogenixX — Funding & Investors." VCBacked, July 6, 2023, https://www.vcbacked.co/company/tolerogenixx. Accessed August 16, 2026.
VCBacked. (2023). TolerogenixX — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/tolerogenixx
{{cite web |title=TolerogenixX — Funding & Investors |url=https://www.vcbacked.co/company/tolerogenixx |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated